Non-alcoholic steatohepatitis (NASH) is characterized by excessive intracellular lipid accumulation, inflammation and hepatic insulin resistance. As the incidence of NASH is increasing worldwide, there is an urgent need to find novel interventional approaches. The pro-inflammatory cytokine IL-1β, generated and released from Kupffer cells, is considered to initiate the development of NASH. AS-1, a synthetic low-molecule mimetic of myeloid differentiation primary response gene 88 (MyD88), disrupts the interaction between the IL-1 receptor and MyD88. Here, we investigated whether AS-1 could attenuate the pathogenesis of NASH with an emphasis on hepatic insulin resistance.
Introduction
Hepatic steatosis, inflammation and hepatic insulin resistance are considered to be important pathological changes in non-alcoholic steatohepatitis (NASH). It has been postulated that excessive intracellular lipid accumulation and pro-inflammatory cytokine production in the liver in both humans and animal models contribute to hepatic insulin resistance and NASH (Rinella and Green, 2004; Samuel et al., 2004; Liu et al., 2010; Finck and Hall, 2015) . In a prototypical murine model of NASH, mice fed a methionine-and choline-deficient (MCD) diet, the transport and storage of triglycerides has been shown to be dysfunctional and leads to the accumulation of intra-hepatic lipids and an increase in gut-derived endotoxin. It is generally believed that two signalling pathways are involved in the generation and release of IL-1β induced by these saturated fatty acids plus LPS. IL-1β is a potent pro-inflammatory cytokine, which induces deleterious effects on metabolism and insulin resistance in key target tissues. The first signal is provided by an unfavourable utilization of fatty acids and increased hepatic triglyceride content, which can be recognized by toll-like receptors that act as an inducer of IL-1β transcription and stimulate pro-IL-1β precursor production. The second signal induces conformational changes in the inflammasome signalling platform in macrophages that activates caspase 1, which converts the pro-IL-1β precursor into the mature secreted form of IL-1β. IL-1β secreted from Kupffer cells (KCs) has also been shown to mediate the induction of insulin resistance in liver-derived cells. Moreover, hepatocytes cultured in conditioned medium from KCs treated with an IL-1 receptor antagonist showed improvements in insulin sensitivity. In addition, IL-1β knockout mice were more sensitive to insulin and protected from high-fat diet (HFD)-induced adipose tissue inflammation as compared with wild-type control animals (McGillicuddy et al., 2011) ; these data are consistent with the promising clinical effects of an IL-1 receptor antagonist on insulin resistance and T2D (Larsen et al., 2007) .
Hydrocinnamoyl-L-valylpyrrolidine (AS-1), a synthetic low molecular-weight TIR/BB-loop mimetic, which contains a tripeptide sequence of the BB-loop [(F/Y)-(V/L/I)-(P/G)] of the TIR domain of MyD88, has been demonstrated to disrupt the interaction of MyD88 with the IL-1RI/IL-1RAcP complex (Bartfai et al., 2003; Davis et al., 2006; Larsen et al., 2007) . More recently, our laboratory found that AS-1 administration significantly attenuated the association between IL-1 receptors and MyD88 induced by myocardial ischaemia/ reperfusion and pressure overload, resulting in decreased NF-κB binding activity and blockade of the MAPK signalling cascades (Cao et al., 2009; Zhu et al., 2011) . These findings prompted us to investigate whether inhibition of the IL-1 receptor/MyD88 interaction by AS-1 could attenuate NASH and hepatic insulin resistance. In the present study, we examined the hypothesis that AS-1 treatment reduces the progression of hepatic steatohepatitis and insulin resistance in a mouse model of NASH. We demonstrated that AS-1-treated MCD-fed db/db mice presented decreased hepatic steatosis, inflammation and insulin resistance compared with the control group. This study has established a new role for AS-1 in the development of hepatic insulin resistance and, thus, AS-1 could be a new therapeutic strategy for the prevention of NASH and hepatic insulin resistance.
Methods

Synthesis of TIR/BB-loop mimetics
AS-1 was prepared as described previously (Bartfai et (Bartfai et al., 2003; Davis et al., 2006) . The crystals of AS-1 were dissolved in DMSO. AS-1 did not demonstrate any significant cytotoxicity, as determined by the MTT assay (Yamaguchi et al., 2007; Zhu et al., 2011) .
Animals and treatments
A mouse model of MCD diet-induced NASH was studied. Eight-week-old male db/db mice (33-41 g) were purchased from the laboratory animal centre of The Academy of Military Medical Sciences (Beijing, China), housed in groups of no more than four mice per cage and maintained in a temperature-and light-controlled facility (22.5°C and 42.5% humidity, under a 12 h/12 h light-dark cycle, using heated wood chip litter as bedding material) in the SPF (specific pathogen free) animal centre of Nanjing Medical University, and permitted ad libitum consumption of water. Mice were fed either the control diet (#A02082003B, Research Diets, USA) or the MCD diet (#A02082002B, Research Diets, USA) for 4 weeks, as previously reported (Anstee et al., 2010) . The experimental animals were randomly divided into six groups schematized in Supporting Information Figure S1 , and randomization was stratified by body weight. MCD dietfed mice were treated with AS-1 50 mg·kg À1 mouse body weight i.p. AS-1 was prepared by mixing one volume of AS-1 in DMSO with three volumes of saline. Vehicle control was prepared by mixing one volume DMSO with three volumes of saline, as previously described (Zhu et al., 2011) . Recombinant murine IL-1 receptor antagonist (rMuIL-1Ra, IL-1Ra, WYBio, Shanghai, China) was administered to mice s.c. in a volume of 100 μL, as previously described (Zhang et al., 2009) . Four weeks later, mice were ventilated after being anaesthetized with a mixture of ketamine (120 mg·kg
À1
, i.p.) and xylazine (6 mg·kg À1 , i.p.). The depth of anaesthesia was monitored by observation of slow breathing, loss of muscular tone and no response to surgical manipulation, mice were killed by cervical dislocation in a room separate from the other experimental animals. The serum and livers were harvested for corresponding analyses. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 2011, eighth edition). All animal experiments fulfilled Nanjing Medical University requirements for humane animal care. The study was carried out in compliance with the replacement, refinement or reduction (the 3Rs).
Histological and immunohistochemical analysis
Standard immunohistochemical analysis with citrate antigen retrieval was performed to localize 3-nitrotyrosine (3-NT) expression as previously described (Dixon et al., 2012) . Standard immunofluorescence analysis was performed to localize F4/80, CD68 expression as previously described Duly et al., 2015) . Haematoxylineosin-stained paraffin-embedded and Oil Red O stained frozen liver tissues isolated from mice were graded for hepatic steatosis and inflammation as described previously (Yamaguchi et al., 2007) . Sirius red was used to evaluate liver fibrosis. To obtain statistical significance, at least five 200 magnification random-field images were taken per slide, and at least five animals per group were scored.
Immunoblot
Immunoblot was performed as described previously (Yamaguchi et al., 2007) 
Immunoprecipitation
Tissues or whole-cell lysates were immunoprecipitated with 2 μg of anti-IRS1, anti-MyD88 anti-NLRP3 (Cell Signaling Technology) overnight at 4°C followed by the addition of 20 μL of protein A/G agarose beads (GE Healthcare, Pittsburgh, PA, USA) at 4°C for 4 h. After being washed three times with cold wash buffer and once with lysis buffer, the immunoprecipitates were resuspended in 30 μL of loading buffer and subjected to western blot using anti-phospho-Ser, anti-phospho-Tyr, anti-IL-1 receptor, anti-apoptosisassociated speck-like protein containing a C-terminal (ASC) for examining the phospho-Ser and phospho-Tyr of IRS1, the association of MyD88 with the IL-1 receptor and NLRP3 with ASC respectively.
Real-time PCR
RNA was extracted and analysed by way of quantitative RT-PCR as described previously (Yamaguchi et al., 2007) . The data were analysed by using the ΔΔCt method and normalized to endogenous control of mouse GAPDH mRNA, and the amount of target gene mRNA expression in each sample was expressed relative to that of th econtrol. Primer sequences for real-time quantitative PCR were designed by Primer Express Software (Thermo Fisher Scientific, Waltham, MA, USA; Supporting Information Table S1 ).
Tissue and serum biochemical measurements
Hepatic lipid content was analysed for total triglycerides (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Serum alanine aminotransferase (ALT) and malondialdehyde (MDA) levels were measured using commercially available assays (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Liver caspase1 activity was analysed by a caspase 1 colorimetric assay kit (R&D Systems, Minneapolis, MN, USA). All procedures were performed by following the manufacturer's instructions.
Glucose and insulin tolerance tests
For insulin tolerance tests (ITT), mice were injected i.p. with insulin [1.2 mU·g À1 body weight (I5500, Sigma-Aldrich, St.
Louis, MO)] after a 5 h fast, and blood glucose levels were measured from whole tail blood with a reflectance glucometer (One Touch Ultra; LifeScan, Milpitas, CA, USA) at intervals of 0, 15, 30, 60 and 120 min after the insulin injection, as previously described (Bril et al., 2014) . Glucose tolerance tests (GTT) were performed by injecting mice with glucose (2 mg·g À1 of body mass, i.p.) according to methods described previously (Gao et al., 2009 ). 
Flow cytometry
ROS levels in liver
Frozen blocks of livers were embedded in OTC, and then 10 μm serial sections were prepared. Sections were stained with dihydroethidium (DHE; 1:1000 dilution, Life Technologies, Carlsbad, CA, USA), incubated for 1 h at room temperature in the dark, followed by 5 min washes, three times, with PBS. The images were observed under a fluorescence microscope.
Enzyme-linked immunosorbent assay (ELISA)
The level of IL-1β in Williams' Medium E was measured using commercial ELISA kits (Elabscience Biotechnology Co., Ltd, Wuhan, China). The Williams' Medium E samples were concentrated 10-fold by ultrafiltration centrifuge tube (Amicon Ultra-0.5, Millipore, Billerica, MA), and measurement was performed according to the instructions of the manufacturer.
Isolation and culture of primary hepatocytes and Kupffer cells
In our study, general hepatocytes and KCs were isolated from C57BL/6J mice, whereas KCs in Supporting Information Figure S3A were isolated from db/db mice. A two-step type IV collagenase perfusion technique in vitro was used to isolate primary hepatocytes. The liver was perfused in situ with isotonic perfusate and then collagenase type IV (Life Technologies, Carlsbad, CA) via the portal vein at 37°C. After the liver homogenate had been centrifuged twice at 50× g (4°C) for 5 min and the residual enzymatic solution washed out, hepatocytes were seeded at a density of 145 000 cm À2 in cell culture plates (Corning, NY, USA). Culture medium, Williams' Medium E (SigmaAldrich, St. Louis, MO), was changed 5 h after seeding. KCs were isolated from the supernatant of the initial centrifugation of the cell suspension. The supernatant, which contained KCs, hepatic stellate cells and liver endothelial cells, was centrifuged at 800× g (4°C) for 10 min and resuspended. The cell suspension was carefully placed on top of a two-level gradient consisting of a 25% Percoll (GE Healthcare) solution on top of a 50% Percoll solution and centrifuged at 400× g, 20 min, 4°C. The cells in the interphase between 25 and 50% Percoll were collected, washed and resuspended. KCs were seeded at a density of 0.5-× 10 6 cells cm À2 on a tissue culture plate and cultured for 15 min. Not adherent non-parenchymal liver cells were removed, while KCs were then maintained in the KC culture medium for at least 12 h overnight.
Glucose production assays
To measure glucose production, hepatocytes were pretreated with AS-1 or DMSO for 15 min and then treated with IL-1β (10 ng·mL À1 ) or vehicle in Williams' Medium E for 24 h, washed and incubated for 4 h in glucose production media (DMEM without glucose or phenol red, supplemented with 1 mM pyruvate, 10 mM lactate). Glucose concentrations in the media were measured enzymatically and normalized to total protein content.
Statistical analysis
The experiments were not performed blind. However, we made an effort to be close to the conditions of blinded assays. All the samples were obtained via the same procedures and treated in the same way. All data were obtained via direct recording of physiological parameters, so that analysis did not include any subjective evaluation. The data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Results are expressed as the mean ± SEM. Significance was established between two groups using Student's t-test, while ANOVA was used for multiple group comparisons followed by Tukey's post hoc test. Tukey's post hoc test was run only if F value achieved P < 0.05 and there was no significant variance in homogeneity. Differences were considered significant at P < 0.05. Data were analysed with GraphPad Prisim-5 statistic software (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Treatment with AS-1 significantly attenuated MCD diet-induced steatohepatitis in db/db mice MCD diet-fed mice are characterized by hepatic steatosis, focal inflammation, hepatocyte necrosis, fibrosis and an elevation in ALT (Samuel et al., 2004; Rinella et al., 2008; Liu et al., 2010) . These histological changes are morphologically similar to those observed in human NASH and rendered more severe in the db/db background (Rinella and Green, 2004; Yamaguchi et al., 2007) . The body weight of MCD diet-fed db/db mice was significantly decreased compared with methionine-and choline-supplemented (MCS) control mice, while no significant difference was observed between vehicle and vehicle plus AS-1 groups ( Figure 1A ). However, AS-1 potently attenuated the liver BJP X Wang et al.
hypertrophy in the MCD-fed group, as demonstrated by gross morphology and liver/body weight ratio ( Figure 1B , C). To further investigate the impact of AS-1 on hepatic steatosis, haematoxylin-eosin staining was performed. Although mild hepatic steatosis was observed in the livers of MCS diet-fed mice livers, the MCD diet induced more severe steatosis with an azonal pattern and diffuse hepatocyte ballooning. The i.p. injection of AS-1 injection slightly improved the liver steatosis and ballooning in the MCD group ( Figure 1D ). Oil Red O staining performed in hepatic cryo-sections further confirmed the above results ( Figure 1D ). The MCD diet increased the histological parameters of liver injury, as assessed by the non-alcoholic fatty liver disease (NAFLD) activity score (Kleiner et al., 2005) . AS-1 treatment ameliorated the MCD diet-induced increases in hepatic inflammation, ballooning and overall NAFLD activity score (Table 1) , confirming the benefit of AS-1 on NASH-associated liver injury. Furthermore, the MCD diet-induced hepatic inflammation was significantly blocked by AS-1 treatment starting 2 weeks after the MCD procedure, which indicates that AS-1 is capable of not only preventing but also reversing MCD-induced liver injury, especially hepatic inflammation ( Figure 1D , Table 1 ). To further examine whether AS-1 exerted its protective role via the IL-1 receptor, we compared the effects of AS-1 with those of an IL-1 receptor antagonist in MCD-fed db/db mice. The IL-1 receptor antagonist significantly blocked the MCD diet-induced liver hypertrophy, hepatic inflammation and changes in NAFLD activity score ( Figure 1C , D, Table 1 ). Liver fibrosis is most notable after 8 weeks of feeding the MCD diet. We demonstrated that liver sections stained with Sirius Red, taken from db/db mice after 4 weeks on the MCD, had negligible (and comparable) collagen deposition around hepatocytes and that fibrosis was mainly detected along hepatic perisinusoidal or periportal spaces. Furthermore, there was also no significant difference among the MCD groups (Supporting Information Figure S2A ). These changes were paralleled by similar levels of hepatic collagen, as defined by hydroxyproline levels (Supporting Information Figure S2B ). Although serum triglycerides were significantly Table 1 Histological analysis of steatosis, inflammation, ballooning and overall NAFLD activity score of liver sections AS-1 and non-alcoholic steatohepatitis BJP decreased in MCD-fed mice compared with MCS-fed mice, there was no difference among the five MCD-fed groups (Supporting Information Table S2 ). Serum ALT levels, a key serum marker of liver injury, were about twofold higher in MCD-fed mice than in MCS-fed db/db mice, and both AS-1 treatment before or after MCD diet and IL-1 receptor antagonist administration markedly decreased these ALT levels ( Figure 1E ).
AS-1 inhibited the activity of Kupffer cells and this is involved in the reduced F4/80 and CD68 expression
KCs are the main source for inflammation in the liver (Yerkovich et al., 2004; Wenfeng et al., 2014 the time when AS-1 treatment was started. The IL-1 receptor antagonist also down-regulated the CD68-positive cells to a similar extent as AS-1 (Figure 2A ). This was further confirmed by the mRNA levels of F4/80 and CD68 detected by real-time PCR, which suggest that both AS-1 and the IL-1 receptor antagonist suppressed the activation of KCs (Figure 2B, C) . CD68 + (F4/80 + ) KCs were further analysed in each group using flow cytometry (Nishikawa et al., 2015) . Again, AS-1 and the IL-1 receptor antagonist blocked the activation of phagocytic KCs in the livers (Supporting Information Figure S3A ).
AS-1 ameliorated MCD diet-induced activation of the NLRP3-ASC inflammasome in vivo NLRP3 inflammasome activation has been reported in the liver of MCD mice (Wen et al., 2011; Dixon et al., 2012) . The cytoplasmic receptor nucleotide-binding domain and leucine rich repeat containing family, pyrin domain containing 3 (NLRP3), the adaptor molecule apoptosis-associated Specklike protein containing a CARD (ASC) and pro-caspase 1 form the NLRP3 inflammasome (Sutterwala et al., 2014) . To biochemically assess the impact of AS-1 on inflammasome activation, we examined the maturation of pro-caspase 1, which could be cleaved to an active 10 kDa fragment that then enzymatically cleaves pro-IL-1β to produce mature IL-1β (Sutterwala et al., 2014) . The MCD diet increased caspase 1 cleavage but less so in the livers of db/db mice injected with AS-1 regardless of the time when AS-1 treatment started ( Figure 3A) . MCD also increased caspase 1 enzymatic activity compared with MCS, and AS-1 repressed that effect (Figure 3  B) . Assembly of the NLRP3 inflammasome requires the association of NLRP3 with ASC oligomers via a homotypic pyrin domain interaction. MCD-fed mice showed an 
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augmented formation of the NLRP3-ASC complex, which could be blocked by AS-1 treatment starting either before or 2 weeks after the MCD diet ( Figure 3C, D) . AS-1 also significantly decreased the mRNA levels of NLRP3 and pro-IL-1β induced by the MCD diet ( Figure 3E, F) . Similarly, in the presence of the IL-1 receptor antagonist, the activation of caspase 1, the abundance of NLRP3-ASC complex and the mRNA levels of NLRP3 and pro-IL-1β were much lower than in the vehicle control group ( Figure 3A -E).
AS-1-administration inhibited MCD diet-induced hepatic oxidative stress/nitrative stress Ashraf and Sheikh, 2015) . MCD significantly induced oxidative and nitrative stress in livers of db/db mice, as evidenced by excessive accumulation of ROS, increased MDA content and 3-NT (a well-established marker of nitrative stress), which were dramatically reduced in the two AS-1-treatment groups ( Figure 4A-D) . Meanwhile, AS-1 significantly decreased the mRNA levels of NADPH oxidase subunits, gp91phox, p22phox and p47phox in MCD-fed db/db mice compared with the DMSO-treated group ( Figure 4E ). NADPH-dependent CYP reductase-associated cytochrome p450 2E1 (CYP2E1) is another major source of hepatic ROS (Leclercq et al., 2000; Ishibe et al., 2009; Das et al., 2013) . Here, we observed a marked increase in CYP2E1 protein expression in MCD-fed groups compared with the control groups, which was reversed by AS-1 ( Figure 4F ). Mice given AS-1 for 2 weeks also showed an obvious trend of reduced hepatic oxidative stress ( Figure 4B, F) . The IL-1 Figure 4A-F) . Collectively, these results suggest that AS-1-treatment significantly attenuates oxidative/nitrative stress following MCD diet, which may contribute to the suppression of inflammasome and IL-1β generation.
AS-1 blocked activation of the NLRP3-ASC inflammasome induced by palmitate/LPS in Kupffer cells
KCs are the resident macrophages in the liver, and they are capable of producing pro-inflammatory cytokines (Yerkovich et al., 2004; Wenfeng et al., 2014) . Gut-derived LPS is thought to play a role in delivering 'a second hit' during the translation from simple steatosis to NASH (Rosso et al., 2014) . Therefore, palmitate plus LPS were employed to stimulate KCs. Although there were no significant differences in the total number of liver F4/80 + liver mononuclear cells among the five groups, CD68 + F4/80 + KCs were dramatically down-regulated in both the AS-1 and IL-1 receptor antagonist-treated groups ( Figure 5A ), which was inconsistent with the CD68 mRNA level ( Figure 5B ). Treating KCs with free fatty acid and LPS stimulated caspase 1 activity, and this was also inhibited by pretreatment with AS-1 ( Figure 5C ). The gene expression of pro-IL-1β in KCs was significantly increased at 4 h in response to palmitate-LPS, and this increase was prevented by AS-1 ( Figure 5D ). We then analysed the secretion of IL-1β protein in the culture medium from KCs. Palmitate-LPS significantly increased the protein levels of IL-1β compared with the vehicle control group. In the AS-1 treated group, the levels of IL-1β were significantly reduced by 65.40% compared with the DMSO-treated group. In the IL-1 receptor antagonist treated group, the levels of IL-1β was also significantly reduced by 52.19% compared with the DMSO-treated group ( Figure 5E ). DHE staining indicated that treatment of KCs with a combination of palmitate-LPS significantly increased the content of ROS, but in both the AS-1 and IL-1 receptor antagonist treated groups, the intracellular ROS level was significantly reduced ( Figure 5F ). Taken together, these data suggest that AS-1 might ameliorate NASH by inhibiting ROS generation, NLRP3 inflammasome activation and IL-1β production in KCs.
AS-1 suppressed MCD diet-induced hepatic insulin resistance
Recent data have shown that MCD-fed db/db mice develop more pronounced hepatic insulin resistance than MCD-fed db/m mice, consistent with the impaired hepatic insulin sensitivity seen in patients with NASH (Sanyal et al., 2001; Rinella and Green, 2004) . We measured serum insulin levels and performed GTT and ITT in each group. There were no differences in the serum insulin levels (Supporting Information Table S2 ), GTT or ITT among the db/db mice Results are means ± SEM. *P < 0.05.
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fed the MCD diet ( Figure 6A ). We subsequently examined the effects of AS-1 on hepatic insulin signalling. The increase in serine phosphorylation reflects the degradation of the IRS1 and thus inhibition of insulin signalling. As shown in Figure 6B , db/db mice fed the MCD diet for 4 weeks showed a marked increase in the protein abundance of total serine phosphorylation of IRS1 compared with the MCS-fed mice, and AS-1 and the IL-1 receptor antagonist antagonized this effect of the MCD diet ( Figure 6B ). We then examined the level of p-IRS1 (Ser 307 ). AS-1 markedly protected MCD-fed mice from more aggravated insulin resistance ( Figure 6C ). It has been reported that AS-1 can specifically block the association of MyD88 with the IL-1 receptor (Cao et al., 2009; Zhu et al., 2011) . Therefore, we examined the effect of AS-1 on the interaction of MyD88 with the IL-1 receptor by immunoprecipitation with a specific antibody against MyD88 followed by immunoblot with a specific antibody against the IL-1 receptor. The MCD diet increased the association of MyD88 with IL-1 receptor compared with the MCS diet, while both AS-1 and the IL-1 receptor antagonist significantly attenuated the association between the IL-1 receptor and MyD88 ( Figure 6D ). shown in Figure 6E , the MCD diet induced a significant increase in the phosphorylation of all three MAPKs compared with the control group, all of which was prevented in AS-1 treated group ( Figure 6E ).
AS-1 prevents the IL-1β-induced disruption of hepatic insulin sensitivity and activation of MAPK and IL-1 receptor signalling in primary hepatocytes
We next addressed whether AS-1 could protect IL-1β from mediating the insulin resistance induced in primary hepatocytes. Primary hepatocytes were directly treated with or without AS-1 (100 μM) for 15 min followed by IL-1β (10-ng·mL À1 ) stimulation for 24 h and finally incubated with or without insulin (100 nM) for 3 min. In contrast to other tissues, hepatic insulin resistance is mainly manifested as abnormal gluconeogenesis. IL-1β stimulation significantly increased the glucose production, and this was reversed in the AS-1 treated group ( Figure 7A ). AS-1 prevented IL-1β from enhancing the phosphorylation of IRS1 at Ser 307 and reduced the total level of serine phosphorylation of IRS1 ( Figure 7B, C) . Furthermore, IL-1β treatment potently reduced insulin-induced phosphorylation of Akt at Thr 308 and Ser 473 , and this effect was reversed by pretreatment with AS-1 ( Figure 7D , E), suggesting that AS-1 improves the IL-1β-induced impairment of insulin signalling in primary hepatocytes. We next examined the effect of AS-1 on the interaction of the IL-1 receptor with MyD88 in IL-1β-stimulated primary hepatocytes. IL-1β significantly increased the association of MyD88 with IL-1 receptors compared with the vehicle control group, while the association between MyD88 and IL-1 receptors in the AS-1 treated group was significantly reduced compared with the DMSO-treated group ( Figure 7F ). We also examined the effect of AS-1 administration on MAPK activation following IL-1β treatment in primary hepatocytes. Relative phospho-JNK/ JNK and phospho-p38/p38 and phospho-ERK/ERK levels were significantly increased by 1.94-fold, 1.91-fold and 1.32-fold respectively compared with the vehicle control group (P < 0.05). In AS-1 pretreated group, the ratio of phospho-JNK/JNK, phospho-p38/p38, and phospho-ERK/ ERK were significantly reduced by 33.4, 31.9 and 16.4% respectively, (P < 0.05) compared with the DMSO vehicle group ( Figure 7G-I) . The administration of the IL-1 receptor antagonist also inhibited IL-1β-induced insulin resistance and activation of MAPKs to a similar extent as AS-1 in primary hepatocytes (Supporting Information Figure S4A ).
Mice treated with AS-1 are protected from IL-1β-induced insulin resistance in vivo
To assess the role of AS-1 on IL-1β associated insulin resistance in vivo, we injected mice with IL-1β in the presence The levels of phospho-JNK/JNK, phospho-p38/p38 and phospho-ERK/ERK were determined by western blot (n = 6). Quantification of the western blot band intensity is shown in the right panels respectively. Results are means ± SEM. *P < 0.05.
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or absence of AS-1 and examined insulin sensitivity by ITT. Mice injected with IL-1β showed decreased insulin sensitivity; however, AS-1-treated mice exposed to IL-1β for 2 h did not show insulin resistance ( Figure 8A ). AS-1 also markedly reduced the phosphorylation of IRS1 at Ser 307 in response to IL-1β in vivo ( Figure 8B ). Moreover, the significantly increased levels of phospho-JNK/JNK, phospho-p38/p38 and phospho-ERK/ERK induced by IL-1β were reversed by pretreatment with AS-1 ( Figure 8C ).
Discussion
In the present study, we showed that a TIR/BB-loop mimetic AS-1 prevented hepatic steatohepatitis and insulin resistance in an MCD diet-induced NASH model. We found that the steatohepatitis-associated inflammation in MCD diet-fed db/db mice was attenuated by AS-1. This was associated with an amelioration of oxidative stress and NLRP3-ASC inflammasome activation. Of importance, AS-1 improved hepatic insulin sensitivity. These effects are likely to be mediated by the disruption of the MyD88-dependent IL-1 receptor signalling pathway, subsequently leading to inhibition of MAPK activation and IL-1β maturation. Our data suggest an important role for the IL-1 receptor signalling pathway in the context of NASH and as such present AS-1 as a potential strategy for the prevention and treatment of NASH. The lipogenic MCD diet leads to intrahepatic lipid accumulation and induces severe liver disease in diabetic db/db mice, which is histologically similar to human NASH (Rinella et al., 2008) . However, this MCD diet model does have drawbacks in that the metabolic status of the mice differs from that in human NASH; a notable weight loss is apparent in the former. Also we needed to perform i.p. injections daily during the experiments, but the MCD diet model is more reliable and convenient compared with other models. We also showed that db/db mice fed an MCD diet for 4 weeks develop phenotypical and histopathological features consistent with NASH, such as enlarged livers, severe liver steatosis, liver injury and lobular inflammation, which are consistent with previous findings (Rinella and Green, 2004) . We observed that AS-1 treatment ameliorated all the aforementioned deleterious effects. Interestingly, AS-1 also decreased the number of CD68 + (F4/80 + ) KCs, suggesting that AS-1 could modulate the population of Kupffer cell subsets (Nishikawa et al., 2015) . From the immunostaining and flow cytometry results, AS-1 increased the number of CD68 + KCs and this might also be involved in the reduction in lipid droplets induced by KCs. It would be of interest to determine whether AS-1 modulates the lipid content of KCs. In addition, AS-1 administration starting 2 weeks after the MCD diet was able to suppress the increase in serum ALT levels, CD68/F4/80 expression and inflammasome activation, indicating an unexpected therapeutic role for AS-1 in stalling the progression of NASH. This 2 week regime of AS-1 also appeared to improve ballooning degeneration and the overall NAFLD activity score, but these effects were not statistically significant. Besides, 2 weeks of administration is not enough for reversing the course of NASH. Although this latter factor is likely, the sample sizes of the M2W + AS-1 group were also not large enough to draw an irrefutable conclusion, any possible extrapolation to patients should consider the effects of longer periods of administration of AS-1, and this constraint will, hopefully, be removed in our future investigations.
As described before, the inability to process excess lipids in a metabolically nontoxic degradation process promotes increased oxidative stress and lipoapoptosis, which sets in motion the beginning of NASH (Liu et al., 2010; Finck and Hall, 2015) . In MCD diet-fed db/db mice, we found oxidative stress was increased, as characterized by elevated ROS, 3-NT and MDA content, and this was ameliorated by AS-1 treatment. CYP2E1 can inhibit fatty acid oxidation in a NADPH-dependent manner producing pro-oxidant species in NASH (Leclercq et al., 2000; Das et al., 2013; Seth et al., 2015) . Increased mRNA levels of NOX subunits (gp91, p22, p47) and enhanced expression of CYP2E1 were also ameliorated by AS-1 administration in MCD-fed db/db mice. In KCs, AS-1 decreased the palmitate plus LPS-induced increased ROS generation. Wen et al. (2011) reported that elevated fatty acid caused by a HFD can activate the NLRP3 inflammasome in macrophages by AMPK-autophagy-ROS signalling pathways. Likewise, in vivo, we observed that AS-1 inhibited the activation of caspase 1, the formation of the NLRP3-ASC complex, as well as the increased mRNA levels of IL-1β and NLRP3 in MCD-fed db/db mice. Moreover, AS-1 inhibited the increased caspase 1 activity and IL-1β production induced by palmitate plus LPS in KCs, in vitro. These data suggest that AS-1 may ameliorate NLRP3 inflammasome activation, at least in part, by inhibiting the generation of ROS.
Some investigators have postulated that peripheral insulin resistance could well play a causal role in hepatic steatosis, while hepatic inflammation and lipid accumulation are regarded as a primary cause of hepatic insulin resistance (Liu et al., 2010; Gruben et al., 2014) . Rinella et al. (2008) reported that db/db mice fed the MCD diet remained hyperinsulinaemic relative to control mice despite significant weight loss and that after improvement of peripheral insulin sensitivity, hepatic insulin signalling is further impaired in the MCD model, consistent with the assertion that hepatic fat accumulation and hepatic insulin resistance can occur
Figure 8
Mice treated with AS-1 are protected from IL-1β-induced insulin resistance in vivo. (A) ITT performed 2 h after IL-1β injection (n = 6). Eight-weekold male C57BL/6J mice were administered AS-1 immediately before an i.p. injection with saline or mouse recombinant IL-1β. Data are shown as the means ± SEM. *P < 0.05: IL-1β versus control; # P < 0.05: IL-1β + DMSO versus control; $ P < 0.05: IL-1β + DMSO versus IL-1β + AS-1. (B)
Phosphorylation level of IRS1 on serine 307 in liver of each group measured by western blot (n = 6). (C) The levels of phospho-JNK/JNK, phospho-p38/p38 and phospho-ERK/ERK were determined by western blot (n = 6). Quantification of the western blot band intensity is shown in the right panels. Data are shown as the mean ± SEM. *P < 0.05.
BJP
without the development of peripheral insulin resistance. Indeed, our results showed that administration of AS-1 significantly inhibited the level of total serine phosphorylation of IRS1 and phosphorylation of IRS1 on Ser 307 and attenuated the effect on hepatic insulin sensitivity, both in accordance with the improvement in inflammation in MCD diet-fed db/db mice. Furthermore, we evaluated IL-1β-induced insulin resistance and showed that exogenous administration of IL-1β leads to an elevation in the serine phosphorylation of IRS1 and an impaired PI3K/Akt pathway in vivo and in vitro, and that these effects were significantly attenuated by pretreatment with AS-1. These results indicate that IL-1β from the KCs plays a critical role in hepatic insulin resistance and that AS-1 can block its effect. The molecular links between hepatic steatosis and insulin resistance are complex and have not been fully delineated. Recent studies have indicated that the IL-1β-activated signalling pathway is involved in the development of insulin resistance. The depletion of IL-1 receptors protects animals against HFD-induced insulin resistance (McGillicuddy et al., 2011b) . We also observed increased IL-1β generation in the liver in MCD diet-fed mice. AS-1 is a TIR/BB-loop mimetic, which specifically disrupts the association between the IL-1 receptor and MyD88 compared to that of TLR4 and MyD88 (Bartfai et al., 2003; Davis et al., 2006; Cao et al., 2009) . Accordingly, our results showed that the MCD diet significantly increases the association between IL-1 receptors and MyD88, activates the stress-sensitive serine/threonine kinase signalling pathways, including JNK, p38 and ERK MAPKs, which results in the development of hepatic steatosis this model, which was prevented in th eAS-1-treated groups. AS-1 treatment prevented the IL-1β-induced association of IL-1 receptors with MyD88, as well as activation of the MAPK signalling cascades, in accordance with previous findings (Cao et al., 2009; Zhu et al., 2011) . There is also accumulating evidence indicating that mice lacking IL-1 receptors spontaneously develop polyarthritis with increasing age and also show enhanced inflammatory responses during wound healing (Horai et al., 2000; Ishida et al., 2006) . Neutralization of IL-1 or administration of a recombinant IL-1 receptor antagonist has been found to attenuate acetaminophen (APAP)-induced liver injury (Blazka et al., 1995; Ishibe et al., 2009) . In our study, we compared the effects of AS-1 with those of an IL-1 receptor antagonist in vivo and in vitro. Treatment with the IL-1 receptor antagonist significantly ameliorated oxidative stress, liver injury and inflammation compared with the vehicle-treated groups. The IL-1 receptor antagonist evoked similar effects as those induced by the AS-1 treatment, which suggests that AS-1 may ameliorate NASH through the IL-1 receptor/MyD88 pathway.
In conclusion, as shown in Figure 9 , we demonstrated that AS-1 can contribute to the attenuation of NASH. The underlying mechanism is multifold: Firstly, AS-1 may inhibit the activation of the NLRP3-ASC inflammasome and postpone the conversion of pro-IL-1β precursor into the mature secreted form of IL-1β in KCs. Secondly, AS-1 may inhibit the generation of ROS in the liver. Thirdly, AS-1 may interrupt the interaction of the IL-1 receptor with MyD88 and inhibit the activation of the MAPK signalling pathway. Of note, these possibilities are not mutually exclusive and may well cooperate to drive IL-1β-induced hepatic insulin resistance. This study thus describes a new role for AS-1 in the development of NASH and hepatic insulin resistance, and AS-1 could be a new therapeutic strategy for the prevention of NASH and hepatic insulin resistance, a complicated metabolic syndrome.
Figure 9
The underlying mechanism of the effects of AS-1.
AS-1 and non-alcoholic steatohepatitis BJP British Journal of Pharmacology (2017) 174 1841-1856 1853 Figure S1 Diagram for animal treatments. Diagram of the different designed mice groups, both in control conditions or after NASH induced by administrating db/db with MCD diet. The animals received further i.p. administration of saline and/or AS-1 or IL-1Ra before kill in day 28. Figure S2 (Thr308) and (E) Insulin-stimulated phosphorylation of Akt (Ser473) were detected by Western blot in primary hepatocytes. (F) Immunoprecipitation was performed with MyD88 antibody followed by immunoblot with anti-IL-1R antibody. (G, H, I ) The levels of phospho-JNK/JNK, phospho-p38/p38, phospho-ERK/ERK, were determined by Western blot (n = 1). Table S1 RT-PCR Primers for Analysis. 
